Menu Search
Equities

Neurocrine Biosciences Inc

NB3:BER

Neurocrine Biosciences Inc

Actions
  • Price (EUR)130.35
  • Today's Change-2.35 / -1.77%
  • Shares traded5.00
  • 1 Year change+39.68%
  • Beta--
Data delayed at least 15 minutes, as of May 03 2024 07:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is focused on discovering and developing pharmaceuticals for the treatment of neurological, endocrine and psychiatric-based diseases and disorders. Its portfolio includes treatments for tardive dyskinesia, Parkinson’s disease, endometriosis and uterine fibroids. Its product pipeline includes INGREZZA (valbenazine), which provides a once-daily dosing treatment option for tardive dyskinesia and has three dosing options (40 milligrams (mg), 60 mg and 80 mg capsules); ONGENTYS (opicapone) is an adjunctive therapy to levodopa/carbidopa in patients with Parkinson’s disease; ORILISSA (elagolix) is used for the management of moderate to severe endometriosis pain in women. Its pipeline also includes DYSVAL (valbenazine), ORIAHNN (elagolix, estradiol, and norethindrone acetate and elagolix capsules), ALKINDI/ALKINDI SPRINKLE (hydrocortisone), and EFMODY (hydrocortisone modified-release hard capsules).

  • Revenue in USD (TTM)1.98bn
  • Net income in USD369.70m
  • Incorporated1996
  • Employees1.45k
  • Location
    Neurocrine Biosciences Inc6027 EDGEWOOD BEND COURTSAN DIEGO 92130United StatesUSA
  • Phone+1 (858) 617-7600
  • Fax+1 (858) 617-7602
  • Websitehttps://www.neurocrine.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.